Ken Keyong Ren is Director at CASI Pharmaceuticals, Inc. (CASI). They have made 1 open-market trade across 1 company since 2016, most recently 2016-01-19.
CIK 0000895051
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $11K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CASI | 7,537 | $2K |
Shares reported on the most recent Form 4, priced at the 2016-01-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CASI | BUY | 2016-01-19 | 2016-01-21 | $0.73 | $11K | +27.1% | +22.9% | +84.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.